Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.

G L Krauss1, M A Johnson, S Sheth

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA. gkrauss@jhmi.edu

Journal of Neurology, Neurosurgery, and Psychiatry
|February 18, 2003
PubMed
Summary

Tiagabine, unlike vigabatrin, does not cause retinal damage in epilepsy patients. This study found tiagabine preserves visual function and electroretinography, unlike vigabatrin which causes visual field constriction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Acta neurologica Scandinavica·2012
Same author

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Neurology·2012
Same author

Lacosamide for the treatment of epilepsy.

Annals of medicine·2012
Same author

Minimizing pharmacodynamic interactions of high doses of lacosamide.

Acta neurologica Scandinavica·2011
Same author

Tolerability and safety of perampanel: two randomized dose-escalation studies.

Acta neurologica Scandinavica·2011
Same author

Cerebellar and thalamic stimulation treatment for epilepsy.

Acta neurochirurgica. Supplement·2007

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Pharmacology

Background:

  • Vigabatrin (an antiepilepsy drug) is linked to retinal injury and electrophysiological changes.
  • Concerns exist that other GABA-ergic antiepilepsy drugs (AEDs), like tiagabine, may cause similar visual disturbances.
  • This study investigates visual function in patients on long-term tiagabine, vigabatrin, or other AEDs.

Purpose of the Study:

  • To compare visual function, including acuity, color vision, perimetry, and electroretinograms, between epilepsy patients on tiagabine, vigabatrin, and other AEDs.
  • To determine if tiagabine, a GABA-reuptake inhibitor, poses a risk of retinal injury similar to vigabatrin.
  • To assess the impact of long-term AED treatment on visual function.

Main Methods:

  • Cross-sectional study design.

Related Experiment Videos

  • Comparison of visual acuity, color vision, static and kinetic perimetry, and electroretinograms (ERGs).
  • Inclusion of adult epilepsy patients on stable AED treatment for over 6 months, categorized into tiagabine, vigabatrin, and control (other AEDs) groups.

    • Main Results:

    • Vigabatrin patients exhibited significant visual field constriction and abnormal ERGs (photopic B wave, oscillatory, flicker responses).
    • Tiagabine patients and control patients showed normal visual fields and ERGs, comparable to healthy controls.
    • No visual function abnormalities were observed in patients taking other GABA-modulating AEDs.

    Conclusions:

    • Tiagabine treatment is associated with normal electroretinography and visual fields, similar to epilepsy control patients.
    • Unlike vigabatrin, tiagabine does not appear to cause retinal injury or visual dysfunction.
    • Differences in retinal drug concentration and mechanisms between vigabatrin and tiagabine likely explain the varying safety profiles regarding visual function.